Chardan Capital Weighs in on Dyne Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:DYN)

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Analysts at Chardan Capital issued their FY2025 EPS estimates for Dyne Therapeutics in a research note issued to investors on Monday, May 6th. Chardan Capital analyst K. Nakae anticipates that the company will post earnings of ($2.94) per share for the year. Chardan Capital currently has a “Buy” rating and a $31.00 target price on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.27) per share.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.17).

A number of other equities research analysts have also recently weighed in on DYN. Stifel Nicolaus lifted their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Piper Sandler boosted their price objective on Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Oppenheimer restated an “outperform” rating and set a $47.00 target price on shares of Dyne Therapeutics in a report on Monday. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of Dyne Therapeutics in a research note on Friday, May 3rd. Finally, Morgan Stanley initiated coverage on shares of Dyne Therapeutics in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $37.75.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $25.69 on Wednesday. Dyne Therapeutics has a fifty-two week low of $6.40 and a fifty-two week high of $30.27. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of -6.47 and a beta of 1.00. The stock has a 50 day moving average of $26.49 and a 200 day moving average of $18.88.

Insider Activity

In other Dyne Therapeutics news, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $22.57, for a total transaction of $4,164,187.57. Following the transaction, the insider now owns 6,631,464 shares of the company’s stock, valued at $149,672,142.48. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $22.57, for a total value of $4,164,187.57. Following the transaction, the insider now owns 6,631,464 shares in the company, valued at approximately $149,672,142.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jason P. Rhodes sold 177,906 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $23.89, for a total value of $4,250,174.34. Following the completion of the transaction, the director now owns 7,148,211 shares in the company, valued at $170,770,760.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,875,432 shares of company stock worth $44,368,530. Corporate insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Fcpm Iii Services B.V. acquired a new stake in Dyne Therapeutics in the fourth quarter valued at $81,543,000. Braidwell LP grew its stake in Dyne Therapeutics by 32.2% in the 3rd quarter. Braidwell LP now owns 1,821,972 shares of the company’s stock valued at $16,325,000 after acquiring an additional 444,100 shares during the last quarter. Vivo Capital LLC increased its holdings in Dyne Therapeutics by 58.0% during the 1st quarter. Vivo Capital LLC now owns 1,635,136 shares of the company’s stock valued at $46,422,000 after acquiring an additional 600,000 shares in the last quarter. Jennison Associates LLC raised its position in Dyne Therapeutics by 495.2% during the first quarter. Jennison Associates LLC now owns 1,207,551 shares of the company’s stock worth $34,282,000 after acquiring an additional 1,004,680 shares during the last quarter. Finally, Armistice Capital LLC lifted its holdings in shares of Dyne Therapeutics by 31.6% in the third quarter. Armistice Capital LLC now owns 1,200,000 shares of the company’s stock valued at $10,752,000 after purchasing an additional 288,000 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.